Non small Cell Lung Cancer clinical trials newsletter, book excerpts <meta name="keywords" CONTENT="clinical trials lung cancer, newsletter, medical, new cancer treatment, tumor, smoking, non-small cell lung cancer, alternative treatment, clinical trials, diagnosis, chemotherapy, smoking, newsletter, book, new treatment,"> <meta name="description" Content="Current non small-cell clinical trials site devoted to Lung Cancer," <meta http-equiv="Content-Type" content="text/html; charset=windows-1252"><meta name="GENERATOR" content="Microsoft FrontPage 4.0"> <meta name="ProgId" content="FrontPage.Editor.Document"> <meta name="Microsoft Theme" content="expeditn 011, default"></head> <body background="_themes/expeditn/exptextb.jpg" bgcolor="#FFFFFF" text="#000000" link="#993300" vlink="#666600" alink="#CC3300"><font face="book antiqua, times new roman, times"> <p><font size="4">LIST OF NON-SMALL CELL LUNG CANCER CLINICAL TRIAL FROM</font></p> <p><a href="http://cancernet.nci.nih.gov/cgi-bin/srchcgi.exe">http://cancernet.nci.nih.gov/cgi-bin/srchcgi.exe</a></p> <p><a href="clinicaltrialoverviewlungcancer.htm">Lung Cancer clinical trial overview</a> (Understanding lung cancer clinical trials, stages,) </p> </font><table> <tr> <td><font face="book antiqua, times new roman, times"><font size="+1"><b>Title of Clinical Trial</b></font></font></td> <td width="20%"><font face="book antiqua, times new roman, times"><b>Protocol ID<br> Number(s)</b> <td><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>1</b> <input name="GET_SEL_0" type="checkbox" value="199_08740 1"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_08740&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:1:&SFMT=prot_summary/1/0/0">Phase I Dose-Escalating Trial of External Beam Radiotherapy Using Conformal 3-Dimensional Treatment Planning for Nonsmall Cell Lung Cancer (Summary Last Modified 06/1998)</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">MSKCC-91121<br> NCI-V91-0198</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>2</b> <input name="GET_SEL_1" type="checkbox" value="199_14375 2"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_14375&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:2:&SFMT=prot_summary/1/0/0">Phase I Pilot Adjuvant Study of Immunological Parameters Associated With Skin Testing and Vaccination With Autologous Lung Tumor Associated Antigen Plus DetoxPC in Patients With Curatively Resected Stage I, II, or IIIA Non-Small Cell Lung Cancer or Stage I or II Mesothelioma</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">RPCI-DS-96-25<br> NCI-G99-1551</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>3</b> <input name="GET_SEL_2" type="checkbox" value="199_12313 3"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_12313&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:3:&SFMT=prot_summary/1/0/0">Phase I Pilot Study of Active Immunotherapy with Carcinoembryonic Antigen (CEA) Peptide-Pulsed Autologous Dendritic Cells in Metastatic Adenocarcinomas That Express CEA</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">DUMC-96024<br> NCI-H96-1110</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>4</b> <input name="GET_SEL_3" type="checkbox" value="199_13942 4"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_13942&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:4:&SFMT=prot_summary/1/0/0">Phase I Pilot Study of Adenovirus p53 Administered by Bronchoalveolar Lavage in Patients with Bronchoalveolar Cell Lung Carcinoma</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">E-6597</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>5</b> <input name="GET_SEL_4" type="checkbox" value="199_14405 5"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_14405&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:5:&SFMT=prot_summary/1/0/0">Phase I Pilot Study of Thalidomide with Paclitaxel and Carboplatin in Patients with Unresectable Stage IIIA, IIIB, or IV Non-Small Cell Lung Cancer (Summary Last Modified 09/1999)</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">WCCC-CO-99501<br> NCI-T98-0093</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>6</b> <input name="GET_SEL_5" type="checkbox" value="199_10269 6"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_10269&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:6:&SFMT=prot_summary/1/0/0">Phase I Pilot Study of Vaccine Therapy with Tumor-Specific Mutated ras Peptides in Advanced Cancer</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">NCI-94-C-0096D<br> NCI-T93-0152N</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>7</b> <input name="GET_SEL_6" type="checkbox" value="199_14457 7"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_14457&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:7:&SFMT=prot_summary/1/0/0">Phase I Study of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG) in Patients with Advanced Solid Tumors</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">MSKCC-99037<br> NCI-T99-0035</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>8</b> <input name="GET_SEL_7" type="checkbox" value="199_11074 8"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_11074&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:8:&SFMT=prot_summary/1/0/0">Phase I Study of 90Y-Labeled MOAB CC-49 plus Interferon Alfa with and without EDTA and DTPA in Patients with Advanced Non-Small Cell Lung Cancer (Summary Last Modified 09/1999)</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">UAB-9445<br> NCI-B95-0004</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>9</b> <input name="GET_SEL_8" type="checkbox" value="199_11011 9"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_11011&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:9:&SFMT=prot_summary/1/0/0">Phase I Study of a Rebeccamycin Analogue in Patients With Metastatic Epithelial and Mesenchymal Tumors and Malignant Lymphomas (Summary Last Modified 11/1999)</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">WCCC-CO-9493<br> NCI-T94-0118H</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>10</b> <input name="GET_SEL_9" type="checkbox" value="199_13266 10"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_13266&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:10:&SFMT=prot_summary/1/0/0">Phase I Study of Bryostatin 1 Administered in Combination with Paclitaxel and Cisplatin in Patients With Advanced Solid Tumors</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">MSKCC-97139<br> NCI-T97-0118</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>11</b> <input name="GET_SEL_10" type="checkbox" value="199_10994 11"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_10994&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:11:&SFMT=prot_summary/1/0/0">Phase I Study of Bryostatin 1 in Patients with Advanced Cancer (Summary Last Modified 11/1999)</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">GUMC-95332<br> NCI-T94-0200D</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>12</b> <input name="GET_SEL_11" type="checkbox" value="199_13346 12"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_13346&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:12:&SFMT=prot_summary/1/0/0">Phase I Study of Bryostatin 1 Plus Cisplatin in Patients With Metastatic and/or Unresectable Stomach, Esophagus, Anus, Prostate, or Non-Small Cell Lung Cancer</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">LAC-USC-OC971<br> NCI-T97-0072</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>13</b> <input name="GET_SEL_12" type="checkbox" value="199_13552 13"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_13552&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:13:&SFMT=prot_summary/1/0/0">Phase I Study of Carboplatin and Cyclophosphamide with Amifostine for Cytoprotection in Patients with Advanced Malignancies</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">CCF-IRB-1907<br> NCI-V98-1424<br> IMMUNEX-001.G9701</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>14</b> <input name="GET_SEL_13" type="checkbox" value="199_10657 14"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_10657&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:14:&SFMT=prot_summary/1/0/0">Phase I Study of Carboxyamidotriazole Plus Paclitaxel for Advanced Solid Tumors and Refractory Lymphomas</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">NCI-95-C-0015F<br> NCI-T94-0006N<br> NCI-CPB-334</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>15</b> <input name="GET_SEL_14" type="checkbox" value="199_14026 15"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_14026&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:15:&SFMT=prot_summary/1/0/0">Phase I Study of COL-3 in Patients with Advanced Solid Tumors (Summary Last Modified 11/1999)</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">UTHSC-9785011153<br> NCI-T97-0091<br> SACI-IDD-97-27</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>16</b> <input name="GET_SEL_15" type="checkbox" value="199_14421 16"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_14421&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:16:&SFMT=prot_summary/1/0/0">Phase I Study of Decitabine in Patients with Primary Small Cell or Non-Small Cell Lung Cancer</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">NCI-99-C-0129<br> NCI-T99-0012</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>17</b> <input name="GET_SEL_16" type="checkbox" value="199_13835 17"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_13835&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:17:&SFMT=prot_summary/1/0/0">Phase I Study of Dimesna in Patients with Solid Tumor Undergoing Treatment with Cisplastin and Paclitaxel</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">RPCI-DS-9739<br> NCI-G98-1478<br> BIONUM-BNP7787IV101</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>18</b> <input name="GET_SEL_17" type="checkbox" value="199_12272 18"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_12272&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:18:&SFMT=prot_summary/1/0/0">Phase I Study of Docetaxel in Patients with Advanced Malignancy and Varying Degrees of Abnormal Liver Function</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">CHNMC-PHI-08<br> NCI-T96-0028H<br> LAC-USC-PHI-08</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>19</b> <input name="GET_SEL_18" type="checkbox" value="199_13278 19"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_13278&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:19:&SFMT=prot_summary/1/0/0">Phase I Study of Fenretinide in Patients With Solid Malignant Tumors (Summary Last Modified 11/1999)</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">WSU-C-1605<br> NCI-T97-0098</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>20</b> <input name="GET_SEL_19" type="checkbox" value="199_12720 20"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_12720&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:20:&SFMT=prot_summary/1/0/0">Phase I Study of Fluorouracil in Combination with Ethynyluracil and Leucovorin Calcium in Adult Patients with Solid Tumors</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">NCI-97-C-0136B<br> NCI-T97-0025</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>21</b> <input name="GET_SEL_20" type="checkbox" value="199_12633 21"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_12633&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:21:&SFMT=prot_summary/1/0/0">Phase I Study of HER-2/neu Peptide Based Vaccine with Sargramostim (GM-CSF) as an Adjuvant in Patients with Stage III or IV HER-2/neu Expressing Cancers</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">UW-100.1<br> NCI-V97-1259</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>22</b> <input name="GET_SEL_21" type="checkbox" value="199_12652 22"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_12652&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:22:&SFMT=prot_summary/1/0/0">Phase I Study of Inhalation of Interleukin-2 (IL-2) in Patients With Metastatic or Unresectable Cancer</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">LAC-USC-0I951<br> NCI-G97-1264</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>23</b> <input name="GET_SEL_22" type="checkbox" value="199_11261 23"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_11261&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:23:&SFMT=prot_summary/1/0/0">Phase I Study of Irinotecan Administered as a Prolonged Infusion for Adult Solid Tumors</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">NCI-96-C-0013B<br> NCI-T95-0066N<br> NCI-NMOB-9506</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>24</b> <input name="GET_SEL_23" type="checkbox" value="199_14502 24"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_14502&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:24:&SFMT=prot_summary/1/0/0">Phase I Study of Irinotecan and Gemcitabine in Patients With Unresectable or Metastatic Solid Tumors</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">NU-98X3<br> NCI-G99-1588<br> P-UPJOHN-976475157</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>25</b> <input name="GET_SEL_24" type="checkbox" value="199_13367 25"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_13367&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:25:&SFMT=prot_summary/1/0/0">Phase I Study of LMB-9 Immunotoxin for Advanced Carcinomas that Express Lewis Y Antigen</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">NCI-98-C-0078A<br> NCI-T98-0005<br> NCI-MB-400</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>26</b> <input name="GET_SEL_25" type="checkbox" value="199_12996 26"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_12996&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:26:&SFMT=prot_summary/1/0/0">Phase I Study of Oral COL-3 in Patients with Refractory Metastatic Solid Tumors or Lymphoma</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">NCI-98-C-0015F<br> NCI-T97-0082<br> MB-396</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>27</b> <input name="GET_SEL_26" type="checkbox" value="199_11078 27"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_11078&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:27:&SFMT=prot_summary/1/0/0">Phase I Study of Oral Tributyrin, a Butyrate Prodrug, for Refractory Prostate Cancer and Other Solid Tumors</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">UMCC-9421<br> NCI-T94-0181O</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>28</b> <input name="GET_SEL_27" type="checkbox" value="199_09709 28"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_09709&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:28:&SFMT=prot_summary/1/0/0">Phase I Study of Paclitaxel (Taxol) plus Thoracic Radiotherapy for Previously Untreated Stage III Non-Small Cell Lung Cancer</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">VU-VCC-LUN-65<br> NCI-T92-0246D<br> UPCC-3597</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>29</b> <input name="GET_SEL_28" type="checkbox" value="199_13944 29"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_13944&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:29:&SFMT=prot_summary/1/0/0">Phase I Study of Phenylbutyrate Plus Tretinoin in Patients with Acute Promyelocytic Leukemia, Neuroblastoma, Non-small Cell Lung Cancer, or Prostate Cancer</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">MSKCC-98081<br> NCI-T98-0043</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>30</b> <input name="GET_SEL_29" type="checkbox" value="199_14478 30"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_14478&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:30:&SFMT=prot_summary/1/0/0">Phase I Study of PNU 166148 in Patients with Metastatic, Refractory Solid Tumors</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">CRC-BOC-98OMCP001<br> EU-99009<br> P-UPJOHN-98OMCP001</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>31</b> <input name="GET_SEL_30" type="checkbox" value="199_09912 31"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_09912&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:31:&SFMT=prot_summary/1/0/0">Phase I Study of Prolonged Low-Dose Topotecan Infusion Combined with Chest Irradiation in Patients with non-Small Cell Lung Cancer</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">NYU-9301<br> NCI-T93-0015D</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>32</b> <input name="GET_SEL_31" type="checkbox" value="199_14484 32"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_14484&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:32:&SFMT=prot_summary/1/0/0">Phase I Study of Sarcosinamide Nitrosourea (SarCNU) in Patients with Metastatic or Unresectable Solid Tumors</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">DFCI-99046<br> NCI-T98-0082</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>33</b> <input name="GET_SEL_32" type="checkbox" value="199_10769 33"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_10769&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:33:&SFMT=prot_summary/1/0/0">Phase I Study of Simultaneous Topotecan and High Dose Thoracic Radiotherapy for Solid Tumors or Lymphoma</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">WCCC-CO-9492<br> NCI-T94-0099C</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>34</b> <input name="GET_SEL_33" type="checkbox" value="199_14548 34"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_14548&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:34:&SFMT=prot_summary/1/0/0">Phase I Study of ZD1839 in Patients With Advanced Solid Tumors (Summary Last Modified 11/1999)</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">CAN-NCIC-IND122<br> ZENECA-1839IL/0013</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>35</b> <input name="GET_SEL_34" type="checkbox" value="199_12236 35"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_12236&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:35:&SFMT=prot_summary/1/0/0">Phase I Trial of Hydroxyurea for Salvage of Incurable non-Small Cell Lung Cancer</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">CAN-OTT-9501<br> NCI-V96-1099</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>36</b> <input name="GET_SEL_35" type="checkbox" value="199_10444 36"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_10444&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:36:&SFMT=prot_summary/1/0/0">Phase I/II Dose Escalation Study of 3-D Conformal Radiotherapy for Locally Advanced, Inoperable, non-Small Cell Lung Cancer</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">RTOG-9311</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>37</b> <input name="GET_SEL_36" type="checkbox" value="199_14503 37"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_14503&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:37:&SFMT=prot_summary/1/0/0">Phase I/II Study of Carboplatin and Vinorelbine in Patients with Stage IIIB or IV Non-Small Cell Lung Cancer</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">NU-99L2<br> NCI-G99-1589</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>38</b> <input name="GET_SEL_37" type="checkbox" value="199_14384 38"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_14384&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:38:&SFMT=prot_summary/1/0/0">Phase I/II Study of Immunization With MAGE-3 Plus Immunological Adjuvant SB AS-2 in HLA Class I Patients With MAGE-3 Positive Refractory Malignant Tumors</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">EORTC-18972-13971/LUD97-002</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>39</b> <input name="GET_SEL_38" type="checkbox" value="199_14499 39"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_14499&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:39:&SFMT=prot_summary/1/0/0">Phase I/II Study of Induction Chemotherapy With Carboplatin and Gemcitabine Followed By Chemoradiotherapy With Paclitaxel and Vinorelbine in Patients With Locally Advanced Non-Small Cell Lung Cancer</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">NU-99L1<br> NCI-G99-1585</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>40</b> <input name="GET_SEL_39" type="checkbox" value="199_12837 40"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_12837&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:40:&SFMT=prot_summary/1/0/0">Phase I/II Study of Omega-3 Fatty Acids in Advanced Cancer Patients with Cachexia</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">CLB-9473<br> NCI-P97-0097</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>41</b> <input name="GET_SEL_40" type="checkbox" value="199_12724 41"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_12724&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:41:&SFMT=prot_summary/1/0/0">Phase I/II Study of the Combination of Docetaxel, Gemcitabine, and Cisplatin as Induction Chemotherapy in Patients with Stage III Non-Small Cell Lung Cancer</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">MSKCC-97040<br> NCI-G97-1285</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>42</b> <input name="GET_SEL_41" type="checkbox" value="199_13201 42"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_13201&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:42:&SFMT=prot_summary/1/0/0">Phase I/II Study of Twice-Weekly Infusion of Gemcitabine and Concurrent Thoracic Radiation Alone or Following Two Cycles of Cisplatin/Gemcitabine Induction Chemotherapy for Patients with Stage IIIA or IIIB Non-Small Cell Lung Cancer</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">CCCWFU-62197<br> NCI-G98-1386</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>43</b> <input name="GET_SEL_42" type="checkbox" value="199_12611 43"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_12611&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:43:&SFMT=prot_summary/1/0/0">Pilot Study of Low Dose Interleukin-2 Plus Recombinant Human Anti-HER2 Monoclonal Antibody in Patient With Solid Tumors</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">CLB-9661</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>44</b> <input name="GET_SEL_43" type="checkbox" value="199_14477 44"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_14477&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:44:&SFMT=prot_summary/1/0/0">Phase II Adjuvant Study of Immunotherapy With Mutant p53 Peptide Pulsed Autologous Dendritic Cells Following Standard Therapy in Patients With Locally Advanced Non-Small Cell Lung Cancer</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">NCI-99-C-0142<br> NCI-T96-0045<br> VU-VCC-THO-9814</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>45</b> <input name="GET_SEL_44" type="checkbox" value="199_12823 45"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_12823&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:45:&SFMT=prot_summary/1/0/0">Phase II Chemoprotective Study of Amifostine in Combination with Paclitaxel and Carboplatin in Patients with Metastatic Ovarian and Non-Small Cell Lung Cancer</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">UCSF-H57841348101A<br> NCI-V97-1334<br> ALZA-UCSF-H57841348101A</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>46</b> <input name="GET_SEL_45" type="checkbox" value="199_08380 46"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_08380&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:46:&SFMT=prot_summary/1/0/0">Phase II Pilot Study of Active Intralymphatic Immunotherapy with Interferon alfa-Treated Tumor Cells plus Cyclophosphamide in Advanced Cancers (Summary Last Modified 04/1999)</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">SVMC-ONC-222<br> NCI-V91-0075</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>47</b> <input name="GET_SEL_46" type="checkbox" value="199_10906 47"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_10906&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:47:&SFMT=prot_summary/1/0/0">Phase II Pilot Study of Induction with CDDP/VP-16 plus Radiotherapy Followed by Surgery and Adjuvant CDDP/VP-16 for Non-Small Cell Lung Cancer Involving the Superior Sulcus (Pancoast Tumors)</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">SWOG-9416<br> INT-0160</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>48</b> <input name="GET_SEL_47" type="checkbox" value="199_14234 48"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_14234&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:48:&SFMT=prot_summary/1/0/0">Phase II Pilot Study of Monoclonal Antibody HER2 With Carboplatin and Paclitaxel in Patients With HER2 Positive Advanced Non-Small Cell Lung Cancer</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">E-2598</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>49</b> <input name="GET_SEL_48" type="checkbox" value="199_10959 49"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_10959&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:49:&SFMT=prot_summary/1/0/0">Phase II Pilot Study of Tumor-Specific p53 or ras Vaccines with or without Cellular Immunotherapy with Peptide-Activated Lymphocytes plus Interleukin-2</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">NCI-95-C-0105A<br> NCI-T94-0096N</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>50</b> <input name="GET_SEL_49" type="checkbox" value="199_13338 50"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_13338&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:50:&SFMT=prot_summary/1/0/0">Phase II Randomized Study of Amifostine in Patients with Hematologic Malignancies and Solid Tumors Receiving Cyclophosphamide, Etoposide, and Cisplatin Chemotherapy</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">SCRF-98014<br> NCI-V98-1396<br> ALZA-97-49-ii</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>51</b> <input name="GET_SEL_50" type="checkbox" value="199_09405 51"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_09405&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:51:&SFMT=prot_summary/1/0/0">Phase II Randomized Study of Autologous Tumor Cell Vaccine in Patients with Advanced Cancer</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">CBRG-9212<br> NCI-V92-0155<br> NBSG-9212</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>52</b> <input name="GET_SEL_51" type="checkbox" value="199_13856 52"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_13856&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:52:&SFMT=prot_summary/1/0/0">Phase II Randomized Study of Carboplatin and Gemcitabine Followed by Paclitaxel vs Cisplatin and Vinorelbine Followed by Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">SWOG-9806</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>53</b> <input name="GET_SEL_52" type="checkbox" value="199_14568 53"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_14568&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:53:&SFMT=prot_summary/1/0/0">Phase II Randomized Study of Gemcitabine and Docetaxel Versus Gemcitabine and Irinotecan in Chemotherapy Naive Patients With Stage IIIB or IV Non-Small Cell Lung Cancer</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">CLB-39809</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>54</b> <input name="GET_SEL_53" type="checkbox" value="199_13960 54"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_13960&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:54:&SFMT=prot_summary/1/0/0">Phase II Study of 6-Hydroxymethylacylfulvene in Patients with Relapsed or Refractory Non-Small Cell Lung Cancer</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">CLB-39805</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>55</b> <input name="GET_SEL_54" type="checkbox" value="199_12751 55"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_12751&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:55:&SFMT=prot_summary/1/0/0">Phase II Study of Amifostine (Ethyol), Carboplatin (CBDCA), and Paclitaxel (Taxol) in Patients with Stage IIIB and IV Non-Small Cell Lung Cancer (Summary Last Modified 10/1997)</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">UNC-LCCC-9615<br> NCI-V97-1299<br> ALZA-96-004-ii</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>56</b> <input name="GET_SEL_55" type="checkbox" value="199_12820 56"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_12820&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:56:&SFMT=prot_summary/1/0/0">Phase II Study of Amifostine with Paclitaxel, Carboplatin and Concurrent Radiation Therapy for Unresectable Stage II, IIIA, and All Stage IIIB Non-Small Cell Lung Cancer</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">UCMC-967222<br> NCI-V97-1331<br> ALZA-UCMC-967222</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>57</b> <input name="GET_SEL_56" type="checkbox" value="199_13043 57"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_13043&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:57:&SFMT=prot_summary/1/0/0">Phase II Study of Aminocamptothecin Colloidal Dispersion Administered as a 120 Hour Infusion in Patients with Advanced Non-Small Cell Lung Cancer (Summary Last Modified 04/1999)</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">CWRU-1597<br> NCI-T97-0024</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>58</b> <input name="GET_SEL_57" type="checkbox" value="199_13737 58"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_13737&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:58:&SFMT=prot_summary/1/0/0">Phase II Study of Antineoplastons A10 and AS2-1 Capsules in Patients with Non-Small Cell Lung Cancer</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">BRI-LA-10</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>59</b> <input name="GET_SEL_58" type="checkbox" value="199_13731 59"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_13731&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:59:&SFMT=prot_summary/1/0/0">Phase II Study of Antineoplastons A10 and AS2-1 in Patients with Adenocarcinoma of the Lung</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">BRI-LA-3</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>60</b> <input name="GET_SEL_59" type="checkbox" value="199_13732 60"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_13732&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:60:&SFMT=prot_summary/1/0/0">Phase II Study of Antineoplastons A10 and AS2-1 in Patients with Large Cell, Undifferentiated, or Poorly Differentiated Stage IV Lung Cancer (Summary Last Modified 01/1999)</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">BRI-LA-4</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>61</b> <input name="GET_SEL_60" type="checkbox" value="199_13734 61"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_13734&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:61:&SFMT=prot_summary/1/0/0">Phase II Study of Antineoplastons A10 and AS2-1 in Patients with Recurrent or Stage IV Bronchioalveolar Lung Cancer</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">BRI-LA-5</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>62</b> <input name="GET_SEL_61" type="checkbox" value="199_13735 62"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_13735&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:62:&SFMT=prot_summary/1/0/0">Phase II Study of Antineoplastons A10 and AS2-1 in Patients with Recurrent or Stage IV Squamous Cell Lung Cancer</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">BRI-LA-6</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>63</b> <input name="GET_SEL_62" type="checkbox" value="199_13050 63"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_13050&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:63:&SFMT=prot_summary/1/0/0">Phase II Study of Concurrent Radiation, Carboplatin, and Etoposide Followed by Paclitaxel for Poor Risk Stage III Non-Small Cell Lung Cancer (Summary Last Modified 05/1998)</a></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">SWOG-9712</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"><b>64</b> <input name="GET_SEL_63" type="checkbox" value="199_13831 64"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><a href="cgi-bin/srchcgi.exe?TYPE=search&DBID=allprotocol&ZUI=199_13831&PASSTHRU=%3aip%3a206%2e139%2e56%2e37%3a%3aprof%3a:ip:206.139.56.37:prof::recno:64:&SFMT=prot_summary/1/0/0">Phase II Study of Docetaxel in Caucasian and African American Patients with Nonhematologic Cancer of Solid Organs</a> <p> </p> </font></td> <td vAlign="top"><font face="book antiqua, times new roman, times">CLB-9871</font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"><b><font size="4">LINKS </font></b></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"> <p><font color="#000000" face="Verdana" size="3"><a href="lungcancerbook.htm"> <br> The Complete Guide to Lung Cancer</a> <br> The book reviews the nature of the disease, and treatment alternatives at different stages. Go to the entire book site or individual topics </font></p> <p><a href="lungcancerlinksandsites.htm"><font face="Verdana" size="3">Lung cancer links and sites</font></a><font face="Verdana"> An extensive list of lung cancer links and sites, organizations, etc.,</font></p> <p><font color="#000000" face="Verdana" size="3"><b>LUNG CANCER BOOK LINKS</b> </font></p> <p><font color="#000000" face="Verdana" size="3"> Chapter 1-2 <a href="lungcanceroverview.htm">canceroverview</a> </font><font face="Verdana" size="2" color="#000000">how cancer develops, staging, different types of lung cancer, difference between non-small cell and small cell) </font><br> <font color="#000000" face="Verdana" size="3"><br> Chapter 4 <a href="nonsmalllungcancer.htm">nonsmallcell.htm</a><font size="3" color="#000000"> </font><font face="Verdana" size="2" color="#000000">Non-Small Cell lung cancer, treatment categorized by stage, chemotherapy, radiation, </font></font><font face="Verdana" size="2" color="#000000"> </font></p> <p><font color="#000000" face="Verdana" size="3">Chapter 5 <font face="Verdana" size="3"> <a href="smallcelllungcancer.htm">smallcell.htm</a></font><font size="3"> </font><font face="Verdana" size="2">(</font><font face="Verdana" size="2" color="#000000">Small Cell </font></font><font face="Verdana" size="2" color="#000000">overview<font color="#000000" face="Verdana" size="3">,</font> </font></p> <p>Chapter 17 <font size="2"><a href="HMO.htm">HMO.htm</a> (HMO problems and medical insurance issues.</font></p> <p><font face="Verdana" size="2" color="#000000">General Information <a href="lungcancerstages.htm">Lung cancer stages<br> </a></font></p> <p><font color="#000000" face="Verdana" size="3"><strong>Lung Cancer Newsletter</strong> <a href="Newsletter.htm">Newsletter.htm</a></font> <font color="#000000" face="Verdana" size="3"> </font><font face="Verdana" size="2" color="#000000">a detailed quarterly newsletter devoted to recent developments in treatment and diagnosis, learn about the latest medical research, treatments, clinical trials, and chemotherapy.</font></p> <p><font face="Verdana" color="#000000" size="3"><b>Clinical Trials </b><a href="Clinicaltrialslist.htm">Clinical Trials</a>, </font></p> <p><font face="Verdana" size="3" color="#000000"><strong>Legal Issues</strong></font></p> <p><font face="Verdana" size="2">Your right to compensation for exposure to dust in the workplace such as silica or asbestos <br> <a href="compensationforlungcancer.htm">compensationforlungcancer.htm</a> <br> </font><font face="Verdana" size="3"> <br> </font><font face="Arial" size="2">(Note, approximately 25% of lung cancer victims will be entitled to compensation based upon their workplace exposures, but relatively few will actually file claims.)</font></p> <p><font size="2">Medical malpractice </font><font size="2"><font face="Arial"> <a href="failuretodiagnosecancer.htm">failuretodiagnosecancer.htm</a> </font><font face="Verdana" size="3"><br> </font><font face="Verdana"> claims based upon the failure to timely diagnose lung cancer.</font><font face="Verdana" size="3"><br> <br> </font></font><font color="#800000" size="4">Profile</font> </p> <p><font face="Book Antiqua">Howard Gutman is a New Jersey attorney based in Parsippany, New Jersey who has handled numerous legal claims involving lung cancer. A member of the board of directors of a leading cancer support group, he has been an advocate for early lung cancer detection programs and is the author of the upcoming book, A Complete Guide to Lung Cancer. He has appeared on Good Day New York and been interviewed by NBC Nightly News.</font></p> <p><img src="div.gif" alt="[Dividing Line Image]" WIDTH="465" HEIGHT="7"> </p> <h2><font color="#660033"><font color="#800000">Contact Information</font></font></h2> <dl> <dt><strong>Telephone</strong> </dt> <dd> </dd> <dd><font face="Book Antiqua">Howard A. Gutman, 973-257-9400 </font></dd> <dt><font face="Book Antiqua"><strong>FAX</strong> </font></dt> <dd><font face="Book Antiqua">973-257-9128 </font></dd> <dt><font face="Book Antiqua"><strong>Postal address</strong> </font></dt> <dd><font face="Book Antiqua">1259 Route 46, Troy Office Center, Parsippany, New Jersey 07054</font></dd> <dt><font face="Book Antiqua"><strong>Email</strong> </font></dt> <dd><font face="Book Antiqua"><a href="mailto:howian@aol.com"> Howian@aol.com </a></font></dd> </dl> <p><font face="Book Antiqua">The foregoing is intended only to provide general information. For information regarding your particular medical condition, see a qualified physician. </font></p> <p><font color="#000000" face="Verdana" size="3"> </font> <marquee>Get the latest information on lung cancer, order the lung cancer newsletter, call 973-257-9400 for a free trial</marquee> </p> <p> </font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <tr> <td align="right" vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> <td vAlign="top"><font face="book antiqua, times new roman, times"></font></td> </tr> </table><font face="book antiqua, times new roman, times"></font></body> </html>